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Abstract
BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common childhood 
malignancy. This report describes the survival of children with ALL in the United States using the 
most comprehensive and up-to-date cancer registry data.
METHODS: Data from 37 state cancer registries that cover approximately 80% of the US 
population were used. Age-standardized survival up to 5 years was estimated for children aged 0–
14 years who were diagnosed with ALL during 2 periods (2001–2003 and 2004–2009).
RESULTS: In total, 17,500 children with ALL were included. The pooled age-standardized net 
survival estimates for all US registries combined were 95% at 1 year, 90% at 3 years, and 86% at 5 
years for children diagnosed during 2001–2003, and 96%, 91%, and 88%, respectively, for those 
diagnosed during 2004–2009. Black children who were diagnosed during 2001–2003 had lower 5-
year survival (84%) than white children (87%) and had less improvement in survival by 2004–
2009. For those diagnosed during 2004–2009, the 1-year and 5- year survival estimates were 96% 
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and 89%, respectively, for white children and 96% and 84%, respectively, for black children. 
During 2004–2009, survival was highest among children aged 1 to 4 years (95%) and lowest 
among children aged <1 year (60%).
CONCLUSIONS: The current results indicate that overall net survival from childhood ALL in 
the United States is high, but disparities by race still exist, especially beyond the first year after 
diagnosis. Clinical and public health strategies are needed to improve health care access, clinical 
trial enrollment, treatment, and survivorship care for children with ALL.
Keywords
acute lymphoblastic leukemia; childhood cancer; childhood leukemia; leukemia; population-based 
cancer survival
INTRODUCTION
One of the great successes in medicine in the United States has been the increasing survival 
of children with cancer. In the past 50 years, 5-year survival from all cancers combined 
among children in the United States has increased from <60% to nearly 80%.1 Acute 
lymphoblastic leukemia (ALL) is the most common childhood malignancy worldwide, 
accounting for 20% to 30% of overall childhood cancer incidence.2–5 Before 1950, 
childhood ALL was uniformly fatal.6 In the 1960s, 5- year survival for children with ALL in 
the United States was <10%.7,8 Since then, 5-year survival has dramatically improved, from 
57% between 1975 and 1979 to 90% between 2003 and 2009.2,9 This increase in survival is 
consistent with stable incidence rates and decreasing mortality rates.10–12
The progress made in childhood ALL survival in developed countries over the past 4 
decades largely stems from clinical and public health-related cancer control efforts. These 
include increasing clinical trial enrollment, improved supportive care, and risk-directed 
therapy that optimizes the efficacy of existing antileukemic agents.1,13–16 Pediatric cancer 
collaborative treatment groups, which have reported enrollment of over two-thirds of 
patients with childhood ALL over the past 2 decades, have designed randomized clinical 
trials that used risk-adaptive algorithms to adjust the intensity of treatment based on factors 
such as ALL subtype and chromosomal changes, age and white blood-cell count on 
diagnosis, presence of disease in the central nervous system, and persistence of residual 
disease during treatment.8,13,17–19 In addition to improving relapse-free and overall survival, 
a risk-based approach has allowed clinicians to reduce toxicities that contribute to late 
complications and mortality.17
Clinical trials and ensuing advances in risk-based therapy have contributed to the remarkable 
progress in improving clinical outcomes in the United States and other countries.13,14,20 This 
success lies in contrast to 5- year survival below 40% in many developing countries, which 
largely result from abandonment of therapy and high treatment-related mortality.21–23 Five-
year net survival among children diagnosed with ALL previously was estimated at 85% or 
above in the United States, whereas it was still below 50% in several less wealthy countries 
participating in the worldwide cancer survival comparison of the CONCORD-2 study.2,9 
That study established worldwide surveillance of cancer survival in 67 countries using data 
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from over 25 million individuals diagnosed with cancer from 279 cancer registries.9 The 
current report builds on the CONCORD-2 study and describes the survival of children with 
ALL in the United States using the most comprehensive and up-to-date cancer registry data 
available by race and age.
MATERIALS AND METHODS
We used data from 37 state-wide cancer registries funded by the Centers for Disease Control 
and Prevention and the National Cancer Institute that participated in the CONCORD-2 
study, covering approximately 80% of the US population, and consented to inclusion of their 
data in the more detailed analyses reported here.9,24,25 We analyzed individual records for 
17,500 children (ages 0–14 years) who were diagnosed with precursor-cell ALL 
(International Classification of Diseases for Oncology, third edition26 morphology codes 
9727–9729 and 9835–9837) during 2001 through 2009 and were followed until December 
31, 2009. We included all children with ALL in the analyses, even if the child had had a 
previous malignancy. In the extremely rare instance that a child was diagnosed with ALL on 
2 or more occasions during 2001 through 2009, only the first occurrence was considered in 
the survival analyses.
We estimated net survival up to 5 years, with 95% confidence intervals (CIs), for children 
diagnosed during 2001 through 2003 and 2004 through 2009 by race and state. We used the 
Pohar Perme estimator27 of net survival. Net survival can be interpreted as the probability of 
survival up to a given time since diagnosis after controlling for other causes of death 
(background mortality). To control for differences in background mortality between 
participating states by race and over time, we constructed life tables of all-cause mortality in 
the general population for each state from the number of deaths and the population, by 
single year of age, sex, calendar year, and, where possible, by race (black, white), using a 
flexible Poisson model.28 The life tables have been published.29
Children were grouped by diagnosis year into 2 calendar periods (2001–2003 and 2004–
2009) to reflect changes in the methods used by US cancer registries to collect data on stage 
at diagnosis. From 2001 through 2003, most registries coded stage directly from medical 
records to Surveillance, Epidemiology, and End Results Summary Stage 2000.10 Since 2004, 
all registries have derived Summary Stage 2000 using the Collaborative Staging System.11
We estimated net survival using the cohort approach for patients diagnosed during 2001 
through 2003, because all patients had been followed for at least 5 years by December 31, 
2009. We used the complete approach to estimate 5-year net survival for patients diagnosed 
during 2004 through 2009, because 5 years of follow-up data were not available for all 
patients. Net survival was estimated for 4 age groups (ages <1 year and 1–4, 5–9, and 10–14 
years). We obtained age-standardized estimates by assigning equal weights to 3 age-specific 
estimates (0–4, 5–9, and 10–14 years).30 If 2 of the 3 age-specific estimates could not be 
obtained, then we present only the pooled, unstandardized survival estimate for all age 
groups combined (ages 0–14 years). Unstandardized estimates are italicized in Supporting 
Table 1. To explore variation with age in more detail, the first age group was split into 2 
subgroups (Table 1). Trends, geographic variations, and differences in survival by race are 
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presented graphically in bar charts and funnel plots.31 More details on data and methods are 
provided in the accompanying article by Allemani et al.32
RESULTS
Data meeting the eligibility criteria for analyses came from 37 states comprising 80% of the 
total US population (Table 2). Of the 17,500 children with ALL, 83.7% were white, 8.9% 
were black, and 7.4% were of other or unknown race. Almost all cases (98.5%) were 
morphologically verified (Table 2). There were no differences in morphologic verification 
by race.
Figure 1 presents a visual snapshot of the absolute change in 5-year age-standardized net 
survival between the periods 2001 through 2003 and 2004 through 2009 by geographic 
region. For the United States overall, there was an absolute increase in survival of 1.7% 
between those periods.
The 1-year, 3-year, and 5-year age-standardized net survival estimates for all races in the 
pooled US population represented in this study were 95.3% (95% CI, 94.6%–95.9%), 89.7% 
(88.8%–90.7%), and 86.4% (95% CI, 85.3%–87.4%), respectively, during 2001 through 
2003, and 95.7% (95.3%–96.1%), 90.7% (90%–91.4%), and 88.1% (87.2%–88.9%), 
respectively, during 2004 through 2009 (Table 3). Despite these increases in survival, 
disparities still exist between racial groups. For the period 2001 to 2003, 5-year net survival 
was 86.6% (95% CI, 85.5%–87.7%) for whites but 83.8% (80.3%–87.3%) for blacks. From 
2004 to 2009, 5-year net survival increased marginally for whites (88.6%; 87.6%–89.5%) 
but remained the same for blacks (83.6%; 80.6%–86.6%), resulting in a slight widening of 
the racial divergence in survival during 2001 through 2009. The 5-year age-standardized 
estimates for children diagnosed during 2004 through 2009 ranged from 85.2% to 98.6% in 
the Northeast, from 81.7% to 92.2% in the South, from 87.8% to 90.3% in the Midwest, and 
from 86% to 95.9% in the West (see Table 1).
Five-year net survival for children aged < 1 year, 1 to 4, 5 to 9, and 10 to 14 years were 
60.5% (53.4%–67.6%), 92.5% (91.5%–93.5%), 89.2% (87.7%–90.8%), and 79.4% (76.9%–
81.9%), respectively, during 2001 through 2003, and 60.1% (54.5%–65.7%), 94.5% 
(93.7%–95.3%), 90.4% (89%–91.8%), and 81.5% (79.4%–83.6%), respectively, during 2004 
through 2009 (Table 1). Survival was highest among children aged 1 to 4 years and lowest 
among those aged <1 year, with a 30% difference between these age groups in both periods. 
Survival was consistently slightly higher in girls than in boys, with the largest differences 
observed in infants aged <1 year throughout 2001 through 2009.
Funnel plots (Fig. 2) illustrate the variation in survival between states and by race. Five-year 
age-standardized net survival was generally lower among black children (Fig. 2, solid 
circles) than among white children (Fig. 2, open circles). Net survival estimates for black 
children were only available for 3 states: this is because of the difficulty of constructing life 
tables for blacks in some states and in producing age-standardized estimates of net survival 
due to the small numbers of cases and deaths (see Materials and Methods, above). Similar 
patterns were observed during 2004 through 2009.
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DISCUSSION
In this article, we report the most comprehensive analysis of survival to date among children 
with ALL in the United States, with data from 37 cancer registries covering 80% of the 
national population. We observed that short-term survival from childhood ALL in the United 
States is high. For all participating US states combined, the pooled estimate of 1-year net 
survival for children diagnosed during 2004–2009 was 95.7% (95% CI, 95.3%–96.1%), 
whereas 5-year survival was 88.1% (95% CI, 87.2%–88.9%). These 5-year survival 
estimates from a population-based US cohort are slightly lower but still closely aligned with 
the 5-year survival estimates of 91.4% from the Children’s Oncology Group ALL 
randomized trials for a similar period (2000–2005) and the same age group.8 Our results are 
also within the same range as most countries in Northern and Central Europe5,9 and close to 
those in Canada (90.6%; 95% CI, 88.6%–92.7%) for 2005 through 2009.9 Our results are 
consistent with stable incidence rates and decreasing mortality rates for childhood ALL in 
the United States.10–12
Despite the high overall survival, there were geographic and racial disparities. One-year 
survival for children diagnosed during 2004–2009 ranged from 91.4% to 98.9% in the 
Northeast. Differences in 5-year survival were even larger, ranging from 81.7% to 98.6% 
(see Supporting Table 1). Racial disparities were larger for longer-term survival than for 
shorter-term survival.
Five-year survival for black children was typically 3% to 5% lower than that for white 
children. Geographic differences in survival may be explained in part by survival differences 
between white and black children. Survival is generally lower for black children, and the 
proportion of black children varies by state. However, we observed that survival for black 
children was similar to, if not higher than, that of white children in some states (Supporting 
Table 1). This suggests that the distribution of black and white children does not explain all 
of the geographic differences in survival. Although genetic polymorphisms may partially 
explain racial differences in ALL outcomes,33 these differences are more likely to be the 
reflection of differences in socioeconomic status and access to care.34,35 The survival 
patterns we observed by race are consistent with higher incidence rates among white 
children and higher mortality rates among black children.10–12
The patterns of survival by age at diagnosis are consistent with other data from the United 
States36 and other countries.37 The survival of infants diagnosed with ALL is markedly 
lower than that for any other age group, which reflects the higher proportion in this age 
group of children diagnosed with ALL whose profile shows mixed-lineage leukemia gene 
rearrangements.1 This population-based study confirms previous findings that the highest 
survival is found among children ages 1 to 4 years, with decreasing survival as age increases 
toward adolescence.36 Biologic features of childhood leukemia that vary by age and have 
prognostic implications, such as the DNA index and specific chromosomal rearrangements, 
may explain differences in survival by age group. The current finding that survival 
differences in race were most pronounced at age <1 year or >4 years needs further study.37 
We also observed that, as previously reported,38 boys have lower survival from ALL than 
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girls. This sex difference was more marked in infants, for whom survival was the lowest, and 
it remained in the most recent period (2004–2009).
Five-year survival for patients with ALL in the United States is among the highest in the 
world, and it improved from 83.1% to 87.7% between 1995 and 2009, as reported by the 
CONCORD-2 study.9 The high survival may reflect in part the intensity of clinical 
investigations performed to establish the diagnosis, which would be expected to improve the 
definition of morphologic type and thus the selection of the most appropriate treatment. One 
indicator of the intensity of diagnosis is the percentage of cases for which microscopic 
confirmation of the diagnosis was available. For children diagnosed with ALL during the 
period from 1995 through 2009 covered by the CONCORD-2 study, morphologic 
verification was available for 98.4% of patients among all US registries combined and 
ranged between 85.6% and 100% among participating states.9 Morphologic verification, as 
reported here, was similar among both black and white children diagnosed during 2001 
through 2009. The low percentage of cases for which the diagnosis was based on clinical 
rather than pathologic evidence is not likely to be the result of selective case ascertainment 
among participating cancer registries, because all registries were certified by the North 
American Association of Central Cancer Registries as having met data quality and 
completeness standards.
Clinical Perspective
Important advances in childhood ALL survival have been achieved through both clinical and 
public health efforts. Clinical advances include improved supportive care and recognition of 
avenues to reduce the toxicity of therapy without compromising overall outcome. These 
advances in childhood ALL survival have spanned all age groups, races, and both sexes.36 
Clinicians have had increased success with managing the frequent complications of ALL, 
including tumor lysis syndrome, infection during neutropenia, thrombosis, hemorrhage, 
anaphylaxis, and suppression of the hypothalamic-pituitary-adrenal axis.39–41 In addition, 
intrathecal therapy has been used increasingly instead of cranial irradiation for patients with 
central nervous system disease, thereby reducing radiation-associated morbidity and 
mortality.33,42 There has been increasing use of immunophe-notyping and cytogenetic 
characterization to predict outcome and relapse and thus to guide risk-based adjustments in 
therapy.6‘17 Advanced genetic characterization of ALL can contribute to improved 
diagnostic evaluation and enhance clinicians’ ability to monitor the response to therapy.17,43 
In addition, recent geno-typing techniques have allowed clinicians to detect germ-line 
differences that may predict response to therapy, as well as chemotherapy-related side 
effects.33
Cancer Control Perspective
Many of these clinical advances have been achieved in conjunction with public health-
related cancer control efforts, including support for clinical trial enrollment.1 Sustained 
efforts by comprehensive cancer control programs to support clinical trial enrollment for 
children with cancer are needed to improve survival even further for children with ALL. 
With survival increasing, cancer control efforts must also focus on the long-term health of 
childhood ALL survivors.20 Treatment of ALL may result in long-term health effects that 
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may adversely affect the long-term health of childhood cancer survivors. Comprehensive 
cancer control programs could encourage the adoption of survivorship care plans and 
support efforts to improve providers’ knowledge of established follow-up guidelines, such as 
the Children’s Oncology Group long-term follow-up guidelines.44 More widespread 
implementation of these guidelines could help improve and harmonize providers’ knowledge 
of potential late effects, screening, evaluation, anticipatory guidance, counseling, and other 
interventions.44
Comprehensive cancer control programs can also support efforts to reduce disparities among 
children with ALL. Although there were negligible differences in 1-year survival by race, 
we observed that black children had lower 5-year survival than white children. This likely 
reflects differences in access to treatment and may be related to socioeconomic status.45–47 
Cancer control efforts that increase access to care among families with lower socio-
economic status may help to reduce racial discrepancies in treatment and outcomes.
Limitations
This study did not include young persons aged 15 to 19 years, because it used the framework 
of the CONCORD-2 study, which used the conventional age range of 0–14 years for 
children in international cancer studies. Because many previous reports include individuals 
aged ≥ 15 years in their definition of childhood leukemia, comparing this study with past 
studies must account for differences in study population age.2,3,10 Records of children 
diagnosed with leukemia were selected for analysis if their International Classification of 
Diseases for Oncology, third edition, morphologic code was 1 of the 6 codes proposed by 
the HAEMACARE Group for ALL.48,49
Although ALL is the most common childhood malignancy worldwide, absolute case 
numbers are generally small, and caution is needed in interpreting the data. Survival was 
estimated separately for each state, and estimates covering approximately 80% of the US 
population were also obtained by pooling the data from all participating states. Survival 
estimates could not be age-standardized for the less populous states, because the data were 
sparse. This limitation applies particularly to the comparison of survival between blacks and 
whites; because, in most states, black children represent fewer than 20% of ALL cases.
Conclusions
Survival from childhood ALL has been improving overall in 37 US states between the 
periods 2001–2003 and 2004–2009. Because of the relative rarity of childhood ALL, 
national and international collaboration groups that pool patient numbers and coordinate 
multicenter research efforts are essential.13 Continued collaboration will be critical in 
reducing the persistent inequalities in survival from childhood ALL as well as in advancing 
treatment for childhood ALL. Similar research efforts will continue to play a central role in 
improving outcomes in other childhood cancers, for which survival is still well below 90%. 
Comprehensive cancer control programs can support efforts to increase clinical trial 
enrollment and providers’ knowledge of established follow-up guidelines and to encourage 
the use of survivorship care plans. Close monitoring of survivors of childhood ALL using 
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population-based cancer registry data are essential to monitor the effect of the 
implementation of new medical and public health strategies aimed at improving survival.
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Figure 1. 
Age-standardized 5-year net survival (%) and absolute change (%) are illustrated for 
children (aged 0–14 years) who were diagnosed with acute lymphoblastic leukemia during 2 
periods (2001–2003 and 2004–2009). The 37 participating states provided 80.6% population 
coverage of the US. Only age-standardized survival estimates are shown. States are grouped 
by geographic region and ranked within each region by the survival estimate for 2004 
through 2009. Dark-colored bars indicate National Program of Cancer Registries (NPCR) 
registries; pale-colored bars, Surveillance, Epidemiology, and End Results (SEER) 
programs; asterisks, registries affiliated with both programs. † indicates change (%) was not 
plotted because at least 1 estimate was not age-standardized.
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Figure 2. 
Age-standardized 5-year net survival (%) is illustrated for children (aged 0–14 years) with 
acute lymphoblastic leukemia, by calendar period of diagnosis. Each data point represents 
the survival estimate for a US state for either blacks (3 states) or whites (27 states).
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